微创泌尿外科杂志

参考文献

[1] Scelo G, Larose TL. Epidemiology and risk factors for kidney cancer[J]. J Clin Oncol,2018,36(36):Jco2018791905.

[2]胡明，范君言，周雄，等.2020年全球肾癌发病与死亡分析[J].中华流行病学杂志，2023,44(4):575-580.

[3] Gong J, Maia MC, Dizman N, et al. Metastasis in renal cell carcinoma:biology and implications for therapy[J]. Asian J Urol,2016,3(4):286-292.

[4] Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma[J]. World J Oncol,2020,11(3):79-87.

[5] Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2019,30(5):706-720.

[6] Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy:a multicenter European study[J]. Cancer,2005,104(7):1362-1371.

[7]宿佳琦，张海梁.局部进展期肾癌综合治疗研究进展[J].肿瘤防治研究，2023,50(6):556-561.

[8] Gleeson JP, Motzer RJ, Lee CH. The current role for adjuvant and neoadjuvant therapy in renal cell cancer[J]. Curr Opin Urol,2019,29(6):636-642.

[9] Ingels A, Campi R, Capitanio U, et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma[J]. Nat Rev Urol,2022,19(7):391-418.

[10] Bex A, Abu-Ghanem Y, Thienen JVV, et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients(pts)with localized renal cell carcinoma(RCC)who are at high risk of relapse after nephrectomy(NeoAvAx)[J]. J Clin Oncol,2022,40(6_suppl):289.

[11] Huang J, Wang Y, Xu F, et al. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma:a singlearm, phase II trial[J]. J Immunother Cancer,2024,12(6):e008475.

[12]马鑫，何志嵩，马潞林，等.机器人肾癌伴静脉癌栓切除术专家共识[J].微创泌尿外科杂志，2023,12(1):1-7.

[13] Kirkali Z, Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion[J].Eur Urol,2007,52(3):658-662.

[14] Blute ML, Leibovich BC, Lohse CM, et al. The Mayo clinic experience with surgical management,complications and outcome for patients with renal cell carcinoma and venous tumour thrombus[J]. BJU Int,2004,94(1):33-41.

[15] Gu L, Peng C, Liang Q, et al. Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus:NEOTAX, a phase 2 study[J]. Signal Transduct Target Ther,2024,9(1):264.

[16] Yip W, Ghoreifi A, Gerald T, et al. Perioperative complications and oncologic outcomes of nephrectomy following immune checkpoint inhibitor therapy:a multicenter collaborative study[J]. Eur Urol Oncol,2023,6(6):604-610.

[17] Choueiri TK, Tomczak P, Park SH, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma[J]. N Engl J Med,2024,390(15):1359-1371.

[18] Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection(IMmotion010):a multicentre, randomised,double-blind, phase 3 trial[J]. Lancet,2022,400(10358):1103-1116.

[19] Motzer RJ, Bex A, Russo P, et al. Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy:Results from Part B of the randomized, phase 3CheckMate 914 trial[J]. J Clin Oncol,2024,42(4_suppl):LBA358.

[20] Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy(CheckMate 914):a double-blind, randomised,phase 3 trial[J]. Lancet,2023,401(10379):821-832.

[21] Allaf M, Kim S, Harshman L, et al. LBA67 Phase III randomized study comparing perioperative nivolumab(nivo)versus observation in patients(Pts)with renal cell carcinoma(RCC)undergoing nephrectomy(PROSPER, ECOG-ACRINEA8143),a National Clinical Trials Network trial[J]. Ann Oncol,2022,33:S1432-S1433.

[22] Allaf ME, Kim SE, Master VA, et al. PROSPER:phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma(RCC)undergoing nephrectomy(ECOG-ACRINEA8143)[J]. J Clin Oncol,2021,39:4596.

[23] National Comprehensive Cancer Network. Kidney Cancer(Version 2.2025)[EB/OL].(2024-12-05).https：//www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

[24] EAU Guidelines.Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.

[25] Riveros C, Huang E, Ranganathan S, et al. Adjuvant immunotherapy in renal cell carcinoma:a systematic review and meta-analysis[J]. BJU Int,2023,131(5):553-561.

[26] Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma:5-year analysis of KEYNOTE-426[J]. J Clin Oncol,2023,41(17_suppl):4501.

[27] Motzer RJ, Porta C, Eto M, et al. Final prespecified overall survival(OS)analysis of CLEAR:4-year follow-up of lenvatinib plus pembrolizumab(L+P)vs sunitinib(S)in patients(pts)with advanced renal cell carcinoma(aRCC)[J]. J Clin Oncol,2023,41(16_suppl):4502.

[28] Tannir NM, Escudier B, McDermott DF, et al.Nivolumab plus ipilimumab(NIVO+IPI)vs sunitinib(SUN)for first-line treatment of advanced renal cell carcinoma(aRCC):Long-term follow-up data from the phase 3 CheckMate 214 trial[J]. J Clin Oncol,2024,42(4_suppl):363.

[29] Yan XQ, Ye MJ, Zou Q, et al. RENOTORCH:Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma(RCC)-A randomized, open-label, phase III study[J]. Ann Oncol,2023,34(suppl_2):S1013.

[30] Sheng X, Shen P, Qu W, et al. LBA76 Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450)versus sunitinib in first-line treatment of advanced renal cell carcinoma(RCC):A randomized, open-label, phase III study(ETER100). Ann Oncol,2024,35:S1263-S1264.

[31] Iacovelli R, Ciccarese C, Buti S, et al. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study[J]. Eur Urol,2024,86(5):411-419.

[32]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）肾癌诊疗指南2024[M].北京：人民卫生出版社，2024..

[33] Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma:Updated results with long-term follow-up of the randomized, open-label, phase 3CheckMate 025 trial[J]. Cancer,2020,126(18):4156-4167.

[34]周莉，许华艳，鄢谢桥，等.特瑞普利单抗联合阿昔替尼在晚期肾癌中的初步应用[J].中华医学杂志，2022,102(2):136-140..

[35] Huang J, Shi G, Wang Y, et al. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma:a retrospective multicenter study[J]. Future Oncol,2022,18(12):1461-1471.

[36] McKay RR, McGregor BA, Xie W, et al. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma:A ResponseBased Phase II Study(OMNIVORE)[J]. J Clin Oncol,2020,38(36):4240-4248.

[37] Choueiri TK, Kluger H, George S, et al. FRACTION-RCC:nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy[J]. J Immunother Cancer,2022,10(11):e005780.

[38] Atkins MB, Jegede OA, Haas NB, et al. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-na?ve patients with advanced nonclear cell renal cell carcinoma(HCRN GU16-260-Cohort B)[J]. J Immunother Cancer,2023,11(3):e004780.

[39] Grimm MO, Esteban E, Barthélémy P, et al. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma(TITAN-RCC):a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol,2023,24(11):1252-1265.

[40] Powles T, Atkins MB, Escudier B, et al. Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in immotion150:a randomized phase 2clinical trial[J]. Eur Urol,2021,79(5):665-673.

[41] Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma(Study 111/KEYNOTE-146):a phase 1b/2study[J]. Lancet Oncol,2021,22(7):946-958.

[42] Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment(CONTACT-03):a multicentre, randomised,open-label, phase 3 trial[J]. Lancet,2023,402(10397):185-195.

[43]中国人民共和国国家卫生健康委员会.肾细胞癌诊疗指南（2022年）[EB/OL].(2021-12-05). http：//www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74/files/71c1a3953bcd42059e1bda2859305cef.pdf.

[44] Grimm MO, Oya M, Choueiri TK, et al. Impact of prior cytoreductive nephrectomy on efficacy in patients with synchronous metastatic renal cell carcinoma treated with avelumab plus axitinib or sunitinib:post hoc analysis from the javelin renal 101 phase 3trial[J]. Eur Urol,2024,85(1):8-12.

[45] Fransen van de Putte EE, van den Brink L, Mansour MA, et al. Indications and outcomes for deferred cytoreductive nephrectomy following immune checkpoint inhibitor combination therapy:can systemic therapy be withdrawn in patients with no evidence of disease?[J]. Eur Urol Open Sci,2023,55(4):15-22.

[46] Deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma:The NORDICSUN-Trial(NORDIC-SUN)[EB/OL].(2024-12-05). https：//classic. clinicaltrials. gov/ct2/show/NCT03977571.

[47] Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE Trial(PROBE)[EB/OL].(2024-12-05).https：//classic.clinicaltrials.gov/ct2/show/NCT04510597.

[48] CYTO reductive surgery in kidney cancer plus immunotherapy and targeted kinase inhibition(Cyto-KIK)[EB/OL].(2024-12-05). https：//classic. clinicaltrials.gov/ct2/show/results/NCT04322955.

[49] McDermott DF, Lee JL, Ziobro M, et al. Open-label, single-arm, phase ii study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma[J]. J Clin Oncol,2021,39(9):1029-1039.

[50] Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma(KEYNOTE-B61):a single-arm, multicentre, phase 2 trial[J]. Lancet Oncol,2023,24(8):881-891.

[51] Bergmann L, Ahrens M, Albiges L, et al. LBA75Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer:results of the SUNNIFORECAST trial[J]. Ann Oncol,2024,35:S1263.

[52] Chen J, Cai D, Gong K, et al. Collecting duct carcinoma of the kidney:analysis of 74 cases from multiple centers[J]. Urology,2022,164(6):163-168.

[53] Tykodi SS, Gordan LN, Alter RS, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma:results from the phase 3b/4 CheckMate 920 trial[J]. J Immunother Cancer,2022,10(2):e003844.

[54] Lee CH, Voss MH, Carlo MI, et al. Phase trial of cabozantinib plus nivolumab in patients with nonclear-cell renal cell carcinoma and genomic correlates[J]. J Clin Oncol,2022,40(21):2333-2341.

[55] Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma[J]. J Immunother Cancer,2018,6(1):9.

[56] National comprehensive cancer network. management of immunotherapy-related toxicities(version1.2025)[EB/OL].(2024-12-25). https：//www.nccn. org/professionals/physician_gls/pdf/immunotherapy.pdf.

[57] Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy:ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol,2022,33(12):1217-1238.

[58]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南2023[M].北京：人民卫生出版社，2023.

[59] Grünwald V, Voss MH, Rini BI, et al. Axitinib plus immune checkpoint inhibitor:evidence-and expert-based consensus recommendation for treatment optimisation and management of related adverse events[J]. Br J Cancer,2020,123(6):898-904.